Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H28N.Br |
| Molecular Weight | 362.347 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].CC[N+](C)(C)C(C)CC(C1=CC=CC=C1)C2=CC=CC=C2
InChI
InChIKey=UVKFSMBPRQBNCH-UHFFFAOYSA-M
InChI=1S/C20H28N.BrH/c1-5-21(3,4)17(2)16-20(18-12-8-6-9-13-18)19-14-10-7-11-15-19;/h6-15,17,20H,5,16H2,1-4H3;1H/q+1;/p-1
| Molecular Formula | BrH |
| Molecular Weight | 80.912 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C20H28N |
| Molecular Weight | 282.443 |
| Charge | 1 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Emepronium bromide (Cetiprina) is a quarternary ammonium compound with anticholinergic effects. It is mainly used in the treatment of urinary frequency, urge and urge incontinence and is usually administered orally and occasionally intramuscularly. Emepronium bromide was introduced into Britain, after having been used in Sweden for a number of years. The drug was advocated especially for elderly patients suffering from nocturia and urgency with incontinence, when these were due to causes other than obstruction. It was also advocated for enuresis and hypertonic bladder states following surgery or radiotherapy.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010-12 |
|
| [A drug seeks its disease]. | 2010-07-22 |
|
| Medical management of overactive bladder. | 2010-04 |
|
| Severe odynophagia in a patient developing after azithromycin intake: a case report. | 2010-02-03 |
|
| Oxybutynin extended release for the management of overactive bladder: a clinical review. | 2009-09-21 |
|
| Drug-induced esophagitis. | 2009 |
|
| Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. | 2006-10-18 |
|
| Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. | 2002 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4024956
Curator's Comment: Emepronium bromide is commercially available as a parenteral solution, (25 mg/ml) for intramuscular use.
Intravenous doses of 1, 5, 10 and 15 mg of emepronium bromide were given to three healthy volunteers.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:01:44 GMT 2025
by
admin
on
Mon Mar 31 19:01:44 GMT 2025
|
| Record UNII |
WZM699L2TL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID50875265
Created by
admin on Mon Mar 31 19:01:44 GMT 2025 , Edited by admin on Mon Mar 31 19:01:44 GMT 2025
|
PRIMARY | |||
|
EMEPRONIUM BROMIDE
Created by
admin on Mon Mar 31 19:01:44 GMT 2025 , Edited by admin on Mon Mar 31 19:01:44 GMT 2025
|
PRIMARY | |||
|
71820
Created by
admin on Mon Mar 31 19:01:44 GMT 2025 , Edited by admin on Mon Mar 31 19:01:44 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110805
Created by
admin on Mon Mar 31 19:01:44 GMT 2025 , Edited by admin on Mon Mar 31 19:01:44 GMT 2025
|
PRIMARY | |||
|
m4885
Created by
admin on Mon Mar 31 19:01:44 GMT 2025 , Edited by admin on Mon Mar 31 19:01:44 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000080217
Created by
admin on Mon Mar 31 19:01:44 GMT 2025 , Edited by admin on Mon Mar 31 19:01:44 GMT 2025
|
PRIMARY | |||
|
SUB06504MIG
Created by
admin on Mon Mar 31 19:01:44 GMT 2025 , Edited by admin on Mon Mar 31 19:01:44 GMT 2025
|
PRIMARY | |||
|
C169941
Created by
admin on Mon Mar 31 19:01:44 GMT 2025 , Edited by admin on Mon Mar 31 19:01:44 GMT 2025
|
PRIMARY | |||
|
71481
Created by
admin on Mon Mar 31 19:01:44 GMT 2025 , Edited by admin on Mon Mar 31 19:01:44 GMT 2025
|
PRIMARY | RxNorm | ||
|
WZM699L2TL
Created by
admin on Mon Mar 31 19:01:44 GMT 2025 , Edited by admin on Mon Mar 31 19:01:44 GMT 2025
|
PRIMARY | |||
|
222-786-6
Created by
admin on Mon Mar 31 19:01:44 GMT 2025 , Edited by admin on Mon Mar 31 19:01:44 GMT 2025
|
PRIMARY | |||
|
2414
Created by
admin on Mon Mar 31 19:01:44 GMT 2025 , Edited by admin on Mon Mar 31 19:01:44 GMT 2025
|
PRIMARY | |||
|
3614-30-0
Created by
admin on Mon Mar 31 19:01:44 GMT 2025 , Edited by admin on Mon Mar 31 19:01:44 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
PARENT -> SALT/SOLVATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |